The KCNQ5 antibody is a crucial tool in neuroscience and cardiovascular research, targeting the potassium voltage-gated channel subfamily Q member 5 (KCNQ5), a key player in regulating cellular excitability. KCNQ5. part of the KCNQ channel family (Kv7), forms homotetramers or heterotetramers with KCNQ3/4 to generate voltage-gated potassium currents (M-currents) that stabilize resting membrane potential. It is widely expressed in the brain, smooth muscle, and sensory neurons, influencing neuronal firing, vascular tone, and pain signaling. Dysregulation of KCNQ5 is linked to neurological disorders (epilepsy, neuropathic pain), cardiovascular diseases (hypertension), and metabolic syndromes. KCNQ5-specific antibodies enable researchers to study its expression patterns, subcellular localization, and functional roles through techniques like Western blot, immunohistochemistry, and immunofluorescence. These antibodies also aid in investigating post-translational modifications and interactions with regulatory proteins (e.g., calmodulin). Recent studies highlight KCNQ5's potential as a therapeutic target, with subtype-selective modulators in development for diseases like migraine and overactive bladder. Validating antibody specificity remains critical due to high homology among KCNQ subunits. Advances in CRISPR/Cas9-based validation and cryo-EM structural studies of KCNQ5 have further refined antibody applications in both basic research and drug discovery pipelines.